Literature DB >> 6531941

A species difference in the presystemic metabolism of carbazeran in dog and man.

B Kaye, J L Offerman, J L Reid, H L Elliott, W S Hillis.   

Abstract

The bioavailability of carbazeran and the metabolism of carbon-14 labelled drug have been studied in the dog and man following oral administration. The drug was moderately well absorbed in both species, but there was a marked difference in bioavailability and in routes of metabolism. In the dog, systemic bioavailability was approx. 68% and biotransformation involved mainly O-demethylation. In man, bioavailability was not measurable and carbazeran was almost completely cleared via 4-hydroxylation of the phthalazine moiety. Thus the lack of detectable pharmacological effect in man following oral administration of the drug appears to be due to presystemic metabolism by a particularly active pathway not found in the dog.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6531941     DOI: 10.3109/00498258409151492

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

Review 1.  Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2018-06-18       Impact factor: 5.153

Review 2.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

3.  Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro-In Vivo Comparisons.

Authors:  David J Wilkinson; Rosalind L Southall; Mingguang Li; Lisa M Wright; Lindsay J Corfield; Thomas A Heeley; Benjamin Bratby; Ranbir Mannu; Sarah L Johnson; Victoria Shaw; Holly L Friett; Louise A Blakeburn; John S Kendrick; Michael B Otteneder
Journal:  AAPS J       Date:  2017-05-04       Impact factor: 4.009

4.  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

Authors:  Hengmiao Cheng; Chunze Li; Simon Bailey; Sangita M Baxi; Lance Goulet; Lisa Guo; Jacqui Hoffman; Ying Jiang; Theodore Otto Johnson; Ted W Johnson; Daniel R Knighton; John Li; Kevin K-C Liu; Zhengyu Liu; Matthew A Marx; Marlena Walls; Peter A Wells; Min-Jean Yin; Jinjiang Zhu; Michael Zientek
Journal:  ACS Med Chem Lett       Date:  2012-11-07       Impact factor: 4.345

5.  Structure-metabolism relationships in human-AOX: Chemical insights from a large database of aza-aromatic and amide compounds.

Authors:  Susan Lepri; Martina Ceccarelli; Nicolò Milani; Sara Tortorella; Andrea Cucco; Aurora Valeri; Laura Goracci; Andreas Brink; Gabriele Cruciani
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-03       Impact factor: 11.205

6.  Time Course of Aldehyde Oxidase and Why It Is Nonlinear.

Authors:  Armina Abbasi; Erickson M Paragas; Carolyn A Joswig-Jones; John T Rodgers; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2019-02-20       Impact factor: 3.922

7.  Species variation in hepatic aldehyde oxidase activity.

Authors:  C Beedham; S E Bruce; D J Critchley; Y al-Tayib; D J Rance
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Oct-Dec       Impact factor: 2.441

Review 8.  Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes.

Authors:  Mineko Terao; Enrico Garattini; Maria João Romão; Silke Leimkühler
Journal:  J Biol Chem       Date:  2020-03-06       Impact factor: 5.157

9.  ecoAO: A Simple System for the Study of Human Aldehyde Oxidases Role in Drug Metabolism.

Authors:  Erickson M Paragas; Sara C Humphreys; Joshua Min; Carolyn A Joswig-Jones; Silke Leimkühler; Jeffrey P Jones
Journal:  ACS Omega       Date:  2017-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.